[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 36912
1. Krenauer A, Moll A, Pönisch W, Schmitz N, Niedobitek G, Niederwieser D, Aigner T: EBV-associated post-transplantation B-cell lymphoproliferative disorder following allogenic stem cell transplantation for acute lymphoblastic leukaemia: tumor regression after reduction of immunosuppression--a case report. Diagn Pathol; 2010;5:21
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EBV-associated post-transplantation B-cell lymphoproliferative disorder following allogenic stem cell transplantation for acute lymphoblastic leukaemia: tumor regression after reduction of immunosuppression--a case report.
  • Epstein-Barr virus (EBV)-associated B-cell post-transplantation lymphoproliferative disorder (PTLD) is a severe complication following stem cell transplantation.
  • This is believed to occur as a result of iatrogenic immunosuppression leading to a relaxation of T-cell control of EBV infection and thus allowing viral reactivation and proliferation of EBV-infected B-lymphocytes.
  • In support of this notion, reduction of immunosuppressive therapy may lead to regression of PTLD.We present a case of an 18-year-old male developing a monomorphic B-cell PTLD 2 months after receiving an allogenic stem cell transplant for acute lymphoblastic leukemia.
  • Nevertheless, the patient died 3 months afterwards due to extensive graft-vs.-host-disease and sepsis.
  • This observation supports the idea that regression of PTLD is mediated by cytotoxic T-cells and is in keeping with the observation that T-cell depletion, represents a major risk factor for the development of PTLD.
  • [MeSH-major] B-Lymphocytes / virology. Epstein-Barr Virus Infections / etiology. Immunocompromised Host. Immunosuppressive Agents / adverse effects. Lymph Nodes / virology. Lymphoproliferative Disorders / virology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery. Stem Cell Transplantation / adverse effects
  • [MeSH-minor] Adolescent. Biopsy. Cell Proliferation. Fatal Outcome. Humans. Lymphocyte Activation. Male. T-Lymphocytes, Cytotoxic / immunology. T-Lymphocytes, Cytotoxic / virology. Transplantation, Homologous. Virus Activation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Immunol. 1984 Sep;87(2):646-58 [6088089.001]
  • [Cites] Lancet. 1984 Mar 17;1(8377):583-7 [6142304.001]
  • [Cites] J Immunol. 1996 Oct 1;157(7):3054-64 [8816415.001]
  • [Cites] Semin Diagn Pathol. 1997 Feb;14(1):8-14 [9044505.001]
  • [Cites] Cancer Surv. 1997;30:143-62 [9547991.001]
  • [Cites] Springer Semin Immunopathol. 1998;20(3-4):389-403 [9870253.001]
  • [Cites] Transplantation. 1998 Dec 27;66(12):1770-9 [9884275.001]
  • [Cites] Lancet. 1964 Mar 28;1(7335):702-3 [14107961.001]
  • [Cites] Annu Rev Med. 2005;56:29-44 [15660500.001]
  • [Cites] Cancer. 2005 Oct 15;104(8):1661-7 [16149091.001]
  • [Cites] Annu Rev Immunol. 2007;25:587-617 [17378764.001]
  • [Cites] Bone Marrow Transplant. 2008 Aug;42(3):181-6 [18516079.001]
  • [Cites] Transpl Infect Dis. 1999 Sep;1(3):204-12 [11428990.001]
  • [Cites] Transpl Infect Dis. 2001 Sep;3(3):177-85 [11493400.001]
  • [Cites] Bone Marrow Transplant. 2003 Feb;31(3):145-55 [12621474.001]
  • [Cites] Tissue Antigens. 2004 Apr;63(4):285-92 [15009802.001]
  • [Cites] Best Pract Res Clin Haematol. 2004 Sep;17(3):401-13 [15498712.001]
  • [Cites] Transplantation. 1988 Apr;45(4):719-27 [2833828.001]
  • (PMID = 20356360.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  • [Other-IDs] NLM/ PMC2853499
  • [General-notes] NLM/ Original DateCompleted: 20100609
  •  go-up   go-down


2. Hansson F, Toporski J, Månsson R, Johansson B, Norén-Nyström U, Jacobsen SE, Wiebe T, Larsson M, Sigvardsson M, Castor A: Exit of pediatric pre-B acute lymphoblastic leukaemia cells from the bone marrow to the peripheral blood is not associated with cell maturation or alterations in gene expression. Mol Cancer; 2008;7:67

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exit of pediatric pre-B acute lymphoblastic leukaemia cells from the bone marrow to the peripheral blood is not associated with cell maturation or alterations in gene expression.
  • BACKGROUND: Childhood pre-B acute lymphoblastic leukemia (ALL) is a bone marrow (BM) derived disease, which often disseminates out of the BM cavity, where malignant cells to a variable degree can be found circulating in the peripheral blood (PB).
  • In addition, the cell sorting procedure revealed that in 2 out of five investigated patients, a significant fraction of the malignant cells had matured beyond the pre-B cell stage.
  • [MeSH-major] Blood Cells / metabolism. Bone Marrow Cells / metabolism. Gene Expression. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Cell Differentiation. Cell Lineage. Cell Movement. Child. Gene Expression Profiling. Humans. Immunoglobulins / metabolism. In Situ Hybridization, Fluorescence. Stromal Cells / metabolism. Vascular Endothelial Growth Factor A / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2000 Dec;14(12):2205-22 [11187912.001]
  • [Cites] Genes Dev. 2000 Aug 15;14(16):1983-91 [10950862.001]
  • [Cites] J Clin Invest. 2000 Aug;106(4):511-21 [10953026.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19069-74 [16354839.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2223-33 [11187913.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2247-56 [11187916.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2267-75 [11187918.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):31-6 [11134512.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):954-8 [12087404.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2951-9 [12730115.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2690-6 [15251979.001]
  • [Cites] J Exp Med. 1996 Dec 1;184(6):2217-29 [8976177.001]
  • [Cites] Blood. 1998 Dec 1;92(11):4150-66 [9834220.001]
  • [Cites] Cell. 2005 Apr 22;121(2):295-306 [15851035.001]
  • [Cites] Nat Med. 2005 Jun;11(6):630-7 [15908956.001]
  • (PMID = 18694513.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0501838
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulins; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC2525657
  •  go-up   go-down


3. Lightfoot TJ, Roman E, Smith MT, Skibola CF: Acute lymphoblastic leukaemia in children - is there a role for MTHFR? Br J Haematol; 2010 Jun;149(5):797-8; author reply 799-800
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukaemia in children - is there a role for MTHFR?
  • [MeSH-major] Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adult. Age Factors. Child. Genetic Predisposition to Disease. Humans. Meta-Analysis as Topic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Lymphoma. 2007 Apr;48(4):786-92 [17454638.001]
  • [Cites] Br J Haematol. 2010 Jan;148(1):3-14 [19775302.001]
  • [Cites] Blood. 2010 May 13;115(19):3923-9 [20101025.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1956-63 [17035405.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12810-5 [10536004.001]
  • [Cites] Eur J Epidemiol. 2006;21(7):501-10 [16897583.001]
  • [Cites] Blood. 2004 Jan 1;103(1):252-7 [12958073.001]
  • [Cites] Haematologica. 2004 Feb;89(2):139-44 [15003888.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):787-94 [15159311.001]
  • [Cites] Am J Hematol. 2003 Jul;73(3):154-60 [12827651.001]
  • [CommentOn] Br J Haematol. 2010 Jan;148(1):3-14 [19775302.001]
  • (PMID = 20148884.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / P42 ES004705; United States / NCI NIH HHS / CA / R01 CA104682
  • [Publication-type] Comment; Letter
  • [Publication-country] England
  • [Chemical-registry-number] EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2)
  • [Other-IDs] NLM/ NIHMS453668; NLM/ PMC3876734
  •  go-up   go-down


Advertisement
4. The biological basis of nursing - cancer William T Blows The biological basis of nursing - cancer Routledge 360pp £;20.99 0 415 32746 6 0415327466 [Formula: see text]. Nurs Stand; 2005 Dec 07;20(13):36

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The biological basis of nursing - cancer William T Blows The biological basis of nursing - cancer Routledge 360pp £;20.99 0 415 32746 6 0415327466 [Formula: see text].
  • : William Blows begins the introduction to this book by stating: 'Life is all about biology.
  • ' He believes most of us are guilty of seeing biology as just a subject, rather than an actual living and happening event around us and driving us.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28001787.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


5. Daniel SV, Vani DH, Smith AM, Hill QA, Menon KV: Obstructive jaundice due to a pancreatic mass: a rare presentation of acute lymphoblastic leukaemia in an adult. JOP; 2010;11(1):72-4
MedlinePlus Health Information. consumer health - Pancreatic Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Obstructive jaundice due to a pancreatic mass: a rare presentation of acute lymphoblastic leukaemia in an adult.
  • CONTEXT: To highlight a rare presentation of acute lymphoblastic leukaemia.
  • Four weeks after presenting, the white cell count became elevated with blasts on the blood film and bone marrow biopsy revealed a precursor B cell acute lymphoblastic leukaemia.
  • CONCLUSION: Acute lymphoblastic leukaemia may mimic common causes of a pancreatic mass such as adenocarcinoma and should be considered as part of the differential diagnosis when atypical features are present.
  • [MeSH-major] Jaundice, Obstructive / diagnosis. Pancreatic Diseases / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male. Organ Size. Pancreas / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20065559.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


6. Reservists seek more support from managers and staff. Nurs Stand; 2008 Oct 22;23(7):12-13

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reservists seek more support from managers and staff.
  • : Being a reservist in the Royal Navy is not all about spending weekends on ships or training for combat.
  • By joining the 1,600 members of the NHS in the UK's reserve forces, nurses can gain key clinical and leadership skills, as well as taking part in life-saving humanitarian missions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28006359.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


7. Wakeford R: Re: 'Population mixing, socio-economic status and incidence of childhood acute lymphoblastic leukaemia in England and Wales--analysis by census ward' and 'Childhood leukaemia and population movements in France, 1990-2003'. Br J Cancer; 2008 Oct 7;99(7):1194; author reply 1191-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Re: 'Population mixing, socio-economic status and incidence of childhood acute lymphoblastic leukaemia in England and Wales--analysis by census ward' and 'Childhood leukaemia and population movements in France, 1990-2003'.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Social Class

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMJ. 1995 Mar 25;310(6982):763-8 [7711579.001]
  • [Cites] Br J Cancer. 2008 Jan 15;98(1):225-31 [18087281.001]
  • [Cites] Br J Cancer. 2008 Mar 11;98(5):1006-11 [18253115.001]
  • [Cites] Br J Cancer. 2006 Jul 3;95(1):102-6 [16755299.001]
  • [CommentOn] Br J Cancer. 2008 Mar 11;98(5):1006-11 [18253115.001]
  • [CommentOn] Br J Cancer. 2008 Jan 15;98(1):225-31 [18087281.001]
  • (PMID = 18827825.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2567074
  •  go-up   go-down


8. Newnham D: Outsidein - the euro health insurance card expires. David Newnham thinks he knows why. Nurs Stand; 2009 Apr 08;23(31):26-27

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outsidein - the euro health insurance card expires. David Newnham thinks he knows why.
  • : Shock, horror, read all about it - millions of European Health Insurance Cards (EHICs) are about to expire.
  • Feckless Brits face Euro- holiday hell.
  • Department of Health (DH) calls in TV doctor.
  • Honestly, anyone would think avian flu had suddenly landed at Gatwick.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27996519.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


9. Bates J: Quality is key. Nurs Stand; 2009 Apr 29;23(34):27

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality is key.
  • : Do you have targets in your life?
  • I suppose we all do.
  • Mine are generally domestic.
  • For example, by next Christmas I will have caught up with the ironing.
  • It is overambitious, I know, and unlikely to happen, but if I do not at least have a target then there is no hope at all.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27991067.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Arestis NJ, Mackinlay GA, Hendry GM: Intussusception in children with ALL receiving chemotherapy for acute lymphoblastic leukaemia. Pediatr Blood Cancer; 2005 Nov;45(6):838-40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intussusception in children with ALL receiving chemotherapy for acute lymphoblastic leukaemia.
  • Acute abdominal complications of chemotherapy are common but the differential diagnosis wide.
  • We describe two cases of intussuception of the bowel in children receiving chemotherapy for acute lymphoblastic leukaemia (ALL) and discuss how a high clinical suspicion is critical for the correct diagnosis to be made rapidly.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Intussusception / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
  • [MeSH-minor] Child. Diagnosis, Differential. Female. Humans. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16047363.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


11. Pimentel JD, Baker M, Woodgyer AJ, Harris OC: Fatal disseminated Blastoschizomyces capitatus (Geotrichum capitatum) in a patient with relapse of acute lymphoblastic leukaemia. Pathology; 2005 Aug;37(4):319-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fatal disseminated Blastoschizomyces capitatus (Geotrichum capitatum) in a patient with relapse of acute lymphoblastic leukaemia.
  • [MeSH-major] Geotrichosis / complications. Geotrichosis / immunology. Neoplasm Recurrence, Local / complications. Opportunistic Infections / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16194836.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


12. Das PK, Malkin D, Ye CC: Florid bone marrow haematogones in a child following treatment for acute lymphoblastic leukaemia. Br J Haematol; 2006 Feb;132(3):254

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Florid bone marrow haematogones in a child following treatment for acute lymphoblastic leukaemia.
  • [MeSH-major] Bone Marrow Cells / pathology. Burkitt Lymphoma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16409289.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


13. Calaminus G, Hense B, Laws HJ, Groeger M, MacKenzie CR, Göbel U: Diphtheria (D) and tetanus (T) antibody values in children with acute lymphoblastic leukaemia (ALL) after treatment according to Co-ALL 05/92. Klin Padiatr; 2007 Nov-Dec;219(6):355-60
Genetic Alliance. consumer health - Tetanus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diphtheria (D) and tetanus (T) antibody values in children with acute lymphoblastic leukaemia (ALL) after treatment according to Co-ALL 05/92.
  • BACKGROUND: Children and adolescents after acute lymphoblastic leukemia are at risk for a prolonged period of immunodeficiency.
  • Factors such as immunity against specific antigens prior to disease (applied baseline vaccination), intensity of treatment and age can play a role in the appearance of antibodies in serum.
  • Prospective multicenter trials starting together with the ALL-treatment should be able to gain more information about the behavior of antibody levels and the risk of infection from vaccine-preventable disease in immunocompromised patients and thus lead to standardized vaccination guidelines such as immunization with conjugate vaccines already during maintenance treatment.
  • [MeSH-major] Antibodies, Bacterial / blood. Diphtheria Toxoid / immunology. Immunologic Memory. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Tetanus Toxoid / immunology
  • [MeSH-minor] Adolescent. Age Factors. Antineoplastic Combined Chemotherapy Protocols. Chi-Square Distribution. Child. Child, Preschool. Diphtheria / immunology. Diphtheria / prevention & control. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunity, Cellular. Male. Risk. Skin Tests. Tetanus / immunology. Tetanus / prevention & control. Time Factors. Vaccination

  • Genetic Alliance. consumer health - Diphtheria.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18050047.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Bacterial; 0 / Diphtheria Toxoid; 0 / Tetanus Toxoid
  •  go-up   go-down


14. Khattab TM, Jastaniah WA, Felimban SK, Elemam N, Abdullah K, Ahmed B: How could improvement in the management of T-cell acute lymphoblastic leukemia be achieved? Experience of Princess Nourah Oncology Center, National Guard Hospital, Jeddah, Saudi Arabia. J Clin Oncol; 2009 May 20;27(15_suppl):10048

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How could improvement in the management of T-cell acute lymphoblastic leukemia be achieved? Experience of Princess Nourah Oncology Center, National Guard Hospital, Jeddah, Saudi Arabia.
  • : 10048 Background: T-cell acute lymphoblastic leukemia (T-ALL) is representing 10-15% of pediatric ALL.
  • Our published data showed that T-ALL phenotype patients fared poorly with 5 year survival of 27% versus 83% for precursor B-ALL (Recent Advances Research Update: 2006, 7; 1, P 51-56).
  • METHODS: Retrospective review of all patients files diagnosed with T-ALL from 1989 until now with data collection including; sex, age, white cell count (WBCs), CNS disease, type of protocol used, length of survival, overall survival, cause of death (toxic, disease).
  • Median WBCs 50,000/Cmm (range: 1.500-619,000/Cmm) and positive CNS at diagnosis 10/52 (20%).
  • Overall survival 27/52 (52%) and 25 pts. died (48%); 15 secondary to disease recurrence (9 on UKALL, 4 BFM, 2 CCG 1961); 4 during induction, 1 fulminant hepatic failure, 1 tumor lysis syndrome, and 4 due to toxicities (mucormycosis, staphylococcal toxic shock syndrome, CMV pneumonia, pseudomonas sepsis).
  • Further risk and response stratification in addition to intensification of therapy for T-cell ALL in our center may prove to be beneficial.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962474.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Lu Q, Zhao A, Shen L: Preoperative transcatheter arterial chemoembolization (TACE) and chemotherapy for hepatic colorectal metastases: Impact on hepatic histology and postoperative outcome. J Clin Oncol; 2009 May 20;27(15_suppl):e15090

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative transcatheter arterial chemoembolization (TACE) and chemotherapy for hepatic colorectal metastases: Impact on hepatic histology and postoperative outcome.
  • : e15090 Background: The objective was to evaluate the effect of preoperative administration of TACE and chemotherapy on hepatic injury and on postoperative outcome in patients with colorectal liver metastases (CRM) Methods: Seventy seven patients underwent hepatic resection for CRM between January 1999 and December 2007 were evaluated.
  • Pathologic review of the non-tumorous liver was performed using established criteria for steatosis, steatohepatitis, and sinusoidal dilation.
  • The effect of two different treatment and hepatotoxicity on postoperative outcome was analyzed.
  • RESULTS: 40 patients (51.9%) received no preoperative treatment, where 27 patients (35.0%) received preoperative chemotherapy, 10 patients (12.9%) performed TACE before resection.
  • The median duration of TACE group was 4.5 months (range, 1-6 months), where the median duration of chemotherapy group was 5 cycles (range, 2-9 cycles).
  • Chemotherapy regimen consisted of oxalipaltin plus FU (29.9%), or irinotecan plus FU (5.2%).
  • On pathologic analysis, 36 patients (46.7%) had steatosis, 24 (31.1%) had sinusoidal dilation, and 8 (10.3%) had steatohepatitis.
  • TACE was associated with steatosis, steatohepatosis and postoperative complication, when compared with no chemotherapy (all p<0.05).Among chemotherapy group,Oxaliplatin was associated with steatohepatitis compared with no preoperative treatment (13.0% v 0%, respectively; p<0.05).
  • Irinotecan was associated with steatohepatitis compared with no preoperative treatment (50% v 0%, respectively; p=0.0006).
  • Patients with preoperative chemotherapy had increased steatohepatitis compared with no treatment group (18.5% v 0%, respectively, p=0.0008), the postoperative morbility rate in preoperative chemotherapy (25.9%) was double that of the no-chemotherapy (12.5%), but this difference was not statistically significant (p=0.20).
  • Preoperative chemotherapy was also not associated with 90-day mortality.
  • CONCLUSIONS: Preoperative TACE treatment may cause pathological liver injury, and increase postoperative morbility after hepatic surgery.
  • The standard preoperative chemotherapy regimen with Oxaliplatin or Irinotecan may increase steatohepatis.
  • No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964609.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Wulfing C, Herrmann E, Trojan L, Schrader A, Becker F, Stähler M, Haferkamp A, Legal W, Brenner W, Hartmann A, German Papillary Renal Cancer Study Group: Independent validation of the 2002 UICC TNM staging system for papillary renal cell carcinoma in a multicenter cohort. J Clin Oncol; 2009 May 20;27(15_suppl):5092

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Independent validation of the 2002 UICC TNM staging system for papillary renal cell carcinoma in a multicenter cohort.
  • : 5092 Background: Papillary renal cell carcinoma (pRCC) is the second most malignant histologic subtype in nephrectomy specimens.
  • Synchronous distant metastases in the entire group occurred in 58 (8.7%) patients and 69 (11.2%) others developed metastatic disease during follow-up.
  • Patients with ≥pT3 were at high risk for metastases (50.6%), while metastatic disease associated with ≤pT2 tumors occurred in 7.8% (p < 0.0001).
  • Once metastatic disease was present, prognosis was poor (5-year CSS: 7.2%).
  • Clinical and radiologic follow-ups should be offered in frequent intervals to patients with venous thrombus and/or locally advanced disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964296.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Nadeem A, Wanebo H, Shrayer D, Hazelwood S, Resnick M: Effect of the apoptosis signal ceramide (C6) on antitumor activity of chemotherapeutic agents in SCID mice. J Clin Oncol; 2009 May 20;27(15_suppl):e14642

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of the apoptosis signal ceramide (C6) on antitumor activity of chemotherapeutic agents in SCID mice.
  • : e14642 Introduction: The ceramides are a major signaling pathway for apoptosis in cells undergoing stress or exposure to chemotherapy.
  • We have demonstrated synergistic anti-tumor effects of combining C6 ceramide with paclitaxel, doxorubicin and cisplatin and are currently addressing the question; does C6 augment activity of all the major classes of drugs?
  • Backround: Currently the in vivo anti-tumor effects of C6 with oxaliplatin and Gemcitabine.
  • METHODS: Invivo experiments SCID/Beige/Taconic male mice inoculated S.C. with 2X106 L3.6 pancreatic cells were treated 4 days post tumor implant with trice weekly (3x/wk) intraperitoneal (IP) injections of paclitaxel (P) 3.0 m/kg, oxaliplatin (OX) 2.5 mg/kg, cisplatin (CP) 2.5 mg/kg, Gemcitabine (Gem) 10 mg/kg with/without ceramide 10 mg/kg.
  • Mice were observed for 6 weeks and were autopsied when near death. (All controls died by 3<sup>rd</sup> week).
  • Maximum tumor volume, tumor weight; body weight and survival were recorded.
  • RESULTS: Combination with C6 ceramide augmented the tumor reduction obtained by chemotherapy alone by 57% (while preserving body weight), and increased 6 week survival from 0% (Chemotherapy alone) to 60% with combined therapy.
  • Mean survival was increased from 25 to 37 days.
  • Although short term immunohistochemical studies suggested enhanced apoptosis and increased caspase 3 production by ceramide combinations it may actually be independent of capase activation and mitochondrial activation.
  • CONCLUSIONS: Combination therapy with the apoptotic signal C6 ceramide significantly enhanced the anti-tumor effects of the anti microtubule, alkylating Paclitaxel a DNA interculating antibiotic (doxorubicin) the alkylating/DNA adducting agents (cisplatin, oxaliplatin) and an anti metabolite (gemcitabine) suggesting generation of broad based apoptotic signals which interact with major cancer drug classes (tested).
  • No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964231.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Pavoni-Ferreira PC, Petrilli AS, Alves MT, Jesus-Garcia Filho R, Toledo SR: Angiogenic biomaker study in osteosarcoma. J Clin Oncol; 2009 May 20;27(15_suppl):e21507

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiogenic biomaker study in osteosarcoma.
  • : e21507 Background: This study represents a prospective assessment of angiogenesis genes mRNA expression in tumors and blood from patients treated with pre- and post-operative Brazilian osteosarcoma protocol (GCBTO 2006) that introduce metronomic chemotherapy (anti-angiogenic) in order to try to increase survival of osteosarcoma patients.
  • METHODS: Tumor samples from 27 patients were analyzed before and after chemotherapy to determine VEGFA, VEGFR1, VEGFR2, PDGFC, SDF1 and TSP1 genes expression profile by Quantitative Real Time PCR.
  • Also, blood samples of these patients were investigated pre- and post-chemotherapy and at the end of high-dose chemotherapy trying to evaluate potential for proangiogenic factors and antiangiogenic factor (TSP1) which could be used to monitor treatment activity.
  • RESULTS: Of all six genes studied pre- and post- chemotherapy, in tumor samples, only SDF1 and VEGFR2 were underexpressed.
  • SDF1 gene has the lowest expression at all.
  • In tumor samples, TSP1 and VEGFA expression was higher than SDF1, VEGFR2 and PDGFC expression in biopsies and surgeries (P=0.001).
  • VEGFR1 expression was higher than VEGFR2 expression (P=0.001).
  • PDGFC and VEGFR1 overexpression were associated with necrosis grade I and II (Huvos score) (P=0.005).
  • VEGFA and TSP1 were overexpressed in 96% and 92% of surgery samples, respectively.
  • In blood samples from biopsy, surgery and end of treatment there were no statistically significant changes in the marker genes expression.
  • CONCLUSIONS: The study suggests an association between PDGFC and VEGFR1 overexpression and lower grade necrosis.
  • TSP1 and VEGFA were the most expressed genes in all tumor samples but TSP1 was lower than VEGFA in biopsies and VEGFA was lower than TSP1 in surgery (P=0.001).
  • Although VEGFR2 is the primary receptor of VEGF, VEGFR1 was the most expressed VEGF receptor.
  • No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963397.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Merrell RT, Lachance DH, Anderson SK: Seizures in patients with glioma treated with phenytoin and levetiracetam. J Clin Oncol; 2009 May 20;27(15_suppl):e13020

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Seizures in patients with glioma treated with phenytoin and levetiracetam.
  • : e13020 Background: Seizures are common in patients with glioma.
  • Phenytoin, traditionally used for these patients, can be associated with intolerable side effects and potentially alters the metabolism of chemotherapeutic agents.
  • Levetiracetam has more favorable pharmacokinetics facilitating ease of use with fewer side effects and is nonenzyme inducing.
  • We compare seizure outcomes and side effects in patients with glioma treated with phenytoin and levetiracetam monotherapy.
  • METHODS: Retrospective analysis of consecutive patients with glioma.
  • Subjects had at least one clinical seizure and had to be followed for 6 months.
  • Seizure outcomes and side effects were compared between cohorts treated with phenytoin or levetiracetam.
  • Seizure outcomes were measured by time to second seizure and seizure frequency.
  • RESULTS: 76 patients (34 female) with pathologically proven glioma and seizures were identified, 25 treated with phenytoin and 51 with levetiracetam.
  • 64% had grade 4 astrocytoma.
  • There was no difference in seizure outcome between the phenytoin and levetiracetam groups when comparing time to second seizure (p = 0.584), second seizure rates (p = 0.462), and average seizures per month (p = 0.776).
  • When adjusting for age, gender, type of seizure, type of glioma, and dosage using univariate and multivariate models there were no differences between the treatment groups and none of these covariates were statistically significant for explaining the second seizure rates between treatment groups (all p values >0.05).
  • The incidence of side effects in the levetiracetam group was 5.9% versus 20% in the phenytoin group (p = 0.106).
  • Additionally, 36.0% of the patients in the phenytoin group had dose adjustments not related to breakthrough seizures compared to only 9.8% in the levetiracetam group (p = 0.010).
  • CONCLUSIONS: In this study, glioma patients treated with levetiracetam had similar seizure control as patients treated with phenytoin.
  • Patients treated with levetiracetam experienced fewer side effects and required fewer non seizure related dose adjustments than patients treated with phenytoin.
  • Levetiracetam is a safe, effective, and preferred alternative for seizure management in patients with glioma.
  • No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962817.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Pavlakis N, Hirsh V, Reck M, Wu Y, Dansin E: MO19390 (SAiL): Incidence of thromboembolic events and congestive heart failure with first-line bevacizumab (Bv)-based therapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):e19003

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MO19390 (SAiL): Incidence of thromboembolic events and congestive heart failure with first-line bevacizumab (Bv)-based therapy in advanced non-small cell lung cancer (NSCLC).
  • METHODS: Key eligibility criteria were untreated locally advanced, metastatic or recurrent non-squamous NSCLC, ECOG PS 0-2, tumor not abutting major blood vessels, no uncontrolled HTN (systolic >150mmHg and/or diastolic >100mmHg) or active cardiovascular disease at baseline.
  • Non-progressors proceeded to receive Bv until disease progression.
  • Pts (%) were: male 60.1; stage IIIB/IV 19.5/80.5 (no data for 3 pts); adenocarcinoma/large cell/other 85.8/7.1/7.1; ECOG PS 0/1/2 38.1/56.1/5.8.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962518.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Yeo W, Goh B, Le Tourneau C, Green SR, Chiao JH, Siu LL: A phase II randomized study of oral seliciclib in patients with previously treated nasopharyngeal carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):6026

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Eligible patients must be ≥18 years with previously treated NPC or other incurable solid tumors; must have measurable disease according to RECIST, ECOG 0-1, and adequate bone marrow, hepatic and renal function.
  • Majority of stable disease occurred in NPC patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962434.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Gilbert J, Lee J, Argiris A, Feldman L, Haigentz M, Burtness B, Forastiere A, Eastern Cooperative Oncology Group: Phase II randomized trial of bortezomib (B) plus irinotecan (I) or B with addition of I at progression in recurrent (R) or metastatic (M) squamous cell carcinoma of the head and neck (SCCHN) (E1304): A trial of the Eastern Cooperative Oncology Group. J Clin Oncol; 2009 May 20;27(15_suppl):6020

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II randomized trial of bortezomib (B) plus irinotecan (I) or B with addition of I at progression in recurrent (R) or metastatic (M) squamous cell carcinoma of the head and neck (SCCHN) (E1304): A trial of the Eastern Cooperative Oncology Group.
  • : 6020 Background: B, inhibits activation of NF- κβ and inhibits growth of SCCHN cell lines.
  • To date, RR low but prolonged stable disease noted in some pts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962416.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Wang XS, Williams LA, Johnson VE, Mao L, Krishnan S, Liao Z, Mobley G, Cleeland CS: Association of sTNF-R1 and the development of treatment-related symptoms in patients undergoing concurrent chemoradiation therapy for colorectal or esophageal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):3041

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Serum samples were tested weekly during therapy for changes in concentration levels of inflammatory cytokines (interleukin [IL]-6, IL-8, IL-10, IL-1 receptor antagonist [IL-1RA], vascular endothelial growth factor [VEGF], and soluble tumor necrosis factor receptor type 1 [sTNF-R1]) via enzyme-linked immunosorbent assay (ELISA).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961980.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Garcia-Manero G, Luger S, Venugopal P, Maness L, Wetzler M, Coutre S, Stock W, Borthakur G, Chiao J, Kantarjian H: A randomized phase II study of sapacitabine, an oral nucleoside analogue, in elderly patients with AML previously untreated or in first relapse or previously treated MDS. J Clin Oncol; 2009 May 20;27(15_suppl):7021

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 7021 Background: Sapacitabine is a novel nucleoside analogue with a unique ability to cause irreparable single-strand DNA breaks and induce G2 cell cycle arrest.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961383.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Grimley PM, Matsuno R, Anderson WF: Population profiles of extra-ovarian and ovarian serous adenocarcinomas: Comparisons with grade stratification. J Clin Oncol; 2009 May 20;27(15_suppl):e16506

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Incidence rates (IR) stratified by grade were compared by year or age of diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960765.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Ikawa Y, Sugimoto N, Koizumi S, Yachie A, Saikawa Y: Promoter DNA methylation of CD10 in infant acute lymphoblastic leukemia with MLL/AF4 fusion gene. J Clin Oncol; 2009 May 20;27(15_suppl):10045

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Promoter DNA methylation of CD10 in infant acute lymphoblastic leukemia with MLL/AF4 fusion gene.
  • While CD10 negativity reflects an earlier stage of B-cell development, complete IgH gene rearrangements (VDJ<sub>H</sub>) show more mature IgH status.
  • METHODS: CD10-negative infant ALL with MLL/AF4, CD10-positive infant ALL with germ-line MLL, CD10-positive pre-B ALL cell line, infant AML (M5) with MLL/AF9 and pediatric AML (M2) with AML1/ETO were analyzed for VDJ<sub>H</sub> status and methylation of CD10 gene promoters.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962471.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Tan DC, Hsu LY, Koh LP, Goh YT, Koh M: Severe conidiobolomycosis complicating induction chemotherapy in a patient with acute lymphoblastic leukaemia. Br J Haematol; 2005 May;129(4):447
Hazardous Substances Data Bank. Itraconazole .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe conidiobolomycosis complicating induction chemotherapy in a patient with acute lymphoblastic leukaemia.
  • [MeSH-major] Conidiobolus. Immunocompromised Host. Military Personnel. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / microbiology. Zygomycosis / diagnosis

  • MedlinePlus Health Information. consumer health - Veterans and Military Health.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15877726.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 304NUG5GF4 / Itraconazole; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


28. Winter PC, McMullin MF, Catherwood MA: Lack of association of the heparanase gene single-nucleotide polymorphism Arg307Lys with acute lymphoblastic leukaemia in patients from Northern Ireland. Leukemia; 2008 Aug;22(8):1629-31; discussion 1631-3
Hazardous Substances Data Bank. (L)-ARGININE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of association of the heparanase gene single-nucleotide polymorphism Arg307Lys with acute lymphoblastic leukaemia in patients from Northern Ireland.
  • [MeSH-major] Arginine / genetics. Glucuronidase / genetics. Lysine / genetics. Polymorphism, Single Nucleotide. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. L-Lysine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Leukemia. 2007 Nov;21(11):2296-303 [17611567.001]
  • (PMID = 18305555.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 94ZLA3W45F / Arginine; EC 3.2.1.- / heparanase; EC 3.2.1.31 / Glucuronidase; K3Z4F929H6 / Lysine
  •  go-up   go-down


29. Tobin AM, Cotter M, Irvine AD, Kirby B: Successful treatment of a refractory verruca in a child with acute lymphoblastic leukaemia with topical cidofovir. Br J Dermatol; 2005 Feb;152(2):386-8
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of a refractory verruca in a child with acute lymphoblastic leukaemia with topical cidofovir.
  • [MeSH-major] Antiviral Agents / therapeutic use. Cytosine / analogs & derivatives. Cytosine / therapeutic use. Foot Dermatoses / drug therapy. Organophosphonates / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Warts / drug therapy

  • MedlinePlus Health Information. consumer health - Warts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15727669.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


30. Barbaric D, Corthals SL, Jastaniah WA, Asalanian S, Shimizu H, Reid GS, Schultz KR: Detection of WT1-specific T cells in paediatric acute lymphoblastic leukaemia patients in first remission. Br J Haematol; 2008 Apr;141(2):271-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of WT1-specific T cells in paediatric acute lymphoblastic leukaemia patients in first remission.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. T-Lymphocyte Subsets / immunology. WT1 Proteins / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18307567.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / WT1 Proteins; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


31. Santoro A, Bica MG, Dagnino L, Agueli C, Salemi D, Cannella S, Veltroni M, Cetica V, Giarin E, Fabbiano F, Basso G, Arico M: Altered mRNA expression of PAX5 is a common event in acute lymphoblastic leukaemia. Br J Haematol; 2009 Sep;146(6):686-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Altered mRNA expression of PAX5 is a common event in acute lymphoblastic leukaemia.
  • [MeSH-major] B-Cell-Specific Activator Protein / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19604238.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / RNA, Messenger
  •  go-up   go-down


32. Linden T, Schnittger S, Groll AH, Juergens H, Rossig C: Childhood B-cell precursor acute lymphoblastic leukaemia in a patient with familial thrombocytopenia and RUNX1 mutation. Br J Haematol; 2010 Dec;151(5):528-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood B-cell precursor acute lymphoblastic leukaemia in a patient with familial thrombocytopenia and RUNX1 mutation.
  • [MeSH-major] Core Binding Factor Alpha 2 Subunit / genetics. Mutation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Thrombocytopenia / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20880108.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / RUNX1 protein, human
  •  go-up   go-down


33. Buggage RR, Myers-Powell B, McManaway J 3rd, Shen D, Robinson MR, Chan CC: Detection of the Philadelphia chromosome in the iris of a child with acute lymphoblastic leukaemia. Histopathology; 2005 Mar;46(3):350-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of the Philadelphia chromosome in the iris of a child with acute lymphoblastic leukaemia.
  • [MeSH-major] Iris / pathology. Philadelphia Chromosome. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15720426.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Interferon; 0 / interferon gamma receptor
  •  go-up   go-down


34. Bharos A, Jong AJ, Manton N, Venn N, Story C, Hodge G, Nath S, Suppiah R, Tapp H, Sutton R, Revesz T: Bone marrow fibrosis and vascular density lack prognostic significance in childhood acute lymphoblastic leukaemia. Leukemia; 2010 Aug;24(8):1537-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow fibrosis and vascular density lack prognostic significance in childhood acute lymphoblastic leukaemia.
  • [MeSH-major] Bone Marrow / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20535149.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


35. de Vries JF, Te Marvelde JG, Wind HK, van Dongen JJ, van der Velden VH: The potential use of basigin (CD147) as a prognostic marker in B-cell precursor acute lymphoblastic leukaemia. Br J Haematol; 2010 Sep;150(5):624-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The potential use of basigin (CD147) as a prognostic marker in B-cell precursor acute lymphoblastic leukaemia.
  • [MeSH-major] Antigens, CD147 / biosynthesis. Biomarkers, Tumor / biosynthesis. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20497175.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 136894-56-9 / Antigens, CD147
  •  go-up   go-down


36. Giebel S, Krawczyk-Kulis M, Kyrcz-Krzemien S, Haus O, Jagoda K, Piatkowska-Jakubas B, Paluszewska M, Seferynska I, Chrobok A, Stella-Holowiecka B, Kielbinski M, Holowiecki J: Could cytogenetics and minimal residual disease replace conventional risk criteria in adults with Ph-negative acute lymphoblastic leukaemia? Br J Haematol; 2009 Mar;144(6):970-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Could cytogenetics and minimal residual disease replace conventional risk criteria in adults with Ph-negative acute lymphoblastic leukaemia?
  • [MeSH-major] Neoplasm, Residual / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19120362.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


37. Whittle AM, Ali S: Primary prophylaxis with voriconazole in patients receiving induction chemotherapy on the MRC adult acute lymphoblastic leukaemia trial (UK-ALL XII) to avoid itraconazole-enhanced vinca neurotoxicity. Int J Lab Hematol; 2008 Apr;30(2):173-4
Hazardous Substances Data Bank. Itraconazole .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary prophylaxis with voriconazole in patients receiving induction chemotherapy on the MRC adult acute lymphoblastic leukaemia trial (UK-ALL XII) to avoid itraconazole-enhanced vinca neurotoxicity.
  • [MeSH-major] Antifungal Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Itraconazole / therapeutic use. Mycoses / prevention & control. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyrimidines / therapeutic use. Triazoles / therapeutic use

  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18333850.001).
  • [ISSN] 1751-5521
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Pyrimidines; 0 / Triazoles; 304NUG5GF4 / Itraconazole; JFU09I87TR / Voriconazole
  •  go-up   go-down


38. Taylor JC, Feltbower RG, McKinney PA, Parslow RC, Law GR: Childhood acute lymphoblastic leukaemia in relation to population mixing around the time of birth in South Hungary. Pediatr Blood Cancer; 2006 Dec;47(7):974; author reply 975

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood acute lymphoblastic leukaemia in relation to population mixing around the time of birth in South Hungary.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Pediatr Blood Cancer. 2006 Dec;47(7):944-8 [16421899.001]
  • (PMID = 16646027.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


39. van Zutven LJ, van Drunen E, de Bont JM, Wattel MM, Den Boer ML, Pieters R, Hagemeijer A, Slater RM, Beverloo HB: CDKN2 deletions have no prognostic value in childhood precursor-B acute lymphoblastic leukaemia. Leukemia; 2005 Jul;19(7):1281-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CDKN2 deletions have no prognostic value in childhood precursor-B acute lymphoblastic leukaemia.
  • [MeSH-major] Gene Deletion. Genes, p16. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15843818.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


40. Jaime-Pérez JC, Rodríguez-Romo LN, González-Llano O, Chapa-Rodríguez A, Gómez-Almaguer D: Effectiveness of intrathecal rituximab in patients with acute lymphoblastic leukaemia relapsed to the CNS and resistant to conventional therapy. Br J Haematol; 2009 Mar;144(5):794-5
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effectiveness of intrathecal rituximab in patients with acute lymphoblastic leukaemia relapsed to the CNS and resistant to conventional therapy.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19036096.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


41. Sonmez M, Cobanoglu U, Ovali E, Omay SB: Use of dasatinib in the patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia with resistance to imatinib and renal failure. J Clin Pharm Ther; 2008 Jun;33(3):329-30
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of dasatinib in the patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia with resistance to imatinib and renal failure.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Piperazines / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyrimidines / therapeutic use. Renal Insufficiency / complications. Thiazoles / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18452422.001).
  • [ISSN] 1365-2710
  • [Journal-full-title] Journal of clinical pharmacy and therapeutics
  • [ISO-abbreviation] J Clin Pharm Ther
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Thiazoles; 8A1O1M485B / Imatinib Mesylate; RBZ1571X5H / Dasatinib
  •  go-up   go-down


42. Chan WM, Liu DT, Lam DS: Images in haematology. Combined central retinal artery and vein occlusions as the presenting signs of ocular relapse in acute lymphoblastic leukaemia. Br J Haematol; 2005 Jan;128(2):134
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Images in haematology. Combined central retinal artery and vein occlusions as the presenting signs of ocular relapse in acute lymphoblastic leukaemia.
  • [MeSH-major] Leukemic Infiltration. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Retinal Artery Occlusion / immunology. Retinal Vein Occlusion / immunology

  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15638846.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


43. Potenza L, Volzone F, Riva G, Soverini S, Martinelli S, Iacobucci I, Gnani A, Barozzi P, Forghieri F, Morselli M, Zanetti E, Maccaferri M, Baccarani M, Martinelli G, Torelli G, Luppi M: Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation. Br J Haematol; 2009 Jul;146(2):227-30
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation.
  • [MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Mutation / genetics. Protein-Tyrosine Kinases / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19545285.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


44. Swords R: Imatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia: a viewpoint by Ronan Swords. Drugs; 2007;67(17):2655-6
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia: a viewpoint by Ronan Swords.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Philadelphia Chromosome. Piperazines / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Pyrimidines / therapeutic use
  • [MeSH-minor] Benzamides. Humans. Imatinib Mesylate. Prognosis. Recurrence. Stem Cell Transplantation. Survival Rate. Transplantation, Homologous

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18034599.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


45. Malone A, Langabeer S, O'Marcaigh A, Storey L, Bacon CL, Smith OP: A doctor(s) dilemma: ETV6-ABL1 positive acute lymphoblastic leukaemia. Br J Haematol; 2010 Oct;151(1):101-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A doctor(s) dilemma: ETV6-ABL1 positive acute lymphoblastic leukaemia.
  • [MeSH-major] Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Protein-Tyrosine Kinases / genetics
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Female. Hematopoietic Stem Cell Transplantation. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20618334.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / TEL-ABL fusion protein, human; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


46. Breitenstein A, Kühne R, Minder EI, Marek A, Goede J, Schanz U, Renner C: Abdominal pain in a patient with acute lymphoblastic leukaemia. Ann Hematol; 2010 Feb;89(2):211-2
MedlinePlus Health Information. consumer health - Abdominal Pain.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abdominal pain in a patient with acute lymphoblastic leukaemia.
  • [MeSH-major] Abdominal Pain / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19588138.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Thiazoles; RBZ1571X5H / Dasatinib
  •  go-up   go-down


47. Wassmann B: Imatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia: a viewpoint by Barbara Wassmann. Drugs; 2007;67(17):2656
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia: a viewpoint by Barbara Wassmann.
  • [MeSH-major] Philadelphia Chromosome. Piperazines / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Pyrimidines / therapeutic use
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Benzamides. Clinical Trials, Phase I as Topic. Clinical Trials, Phase II as Topic. Disease Progression. Drug Resistance, Neoplasm. Drug-Related Side Effects and Adverse Reactions. Humans. Imatinib Mesylate. Point Mutation. Recurrence. Salvage Therapy. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18034598.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


48. Carrasco CD, Yin JL: Spontaneous rupture of the spleen in a patient with B-cell acute lymphoblastic leukaemia. Ann Hematol; 2005 Aug;84(8):555-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous rupture of the spleen in a patient with B-cell acute lymphoblastic leukaemia.
  • [MeSH-major] Burkitt Lymphoma / complications. Spleen / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15815909.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


49. Brandwein J: Imatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia: a viewpoint by Joseph Brandwein. Drugs; 2007;67(17):2655
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia: a viewpoint by Joseph Brandwein.
  • [MeSH-major] Philadelphia Chromosome. Piperazines / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Pyrimidines / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18034600.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 0 / Thiazoles; 8A1O1M485B / Imatinib Mesylate; RBZ1571X5H / Dasatinib
  •  go-up   go-down


50. Milne E, Laurvick CL, Blair E, Bower C, de Klerk N: No sex difference observed in the association between intra-uterine growth and risk of childhood acute lymphoblastic leukaemia. Cancer Causes Control; 2007 Dec;18(10):1227-8; author reply 1229
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No sex difference observed in the association between intra-uterine growth and risk of childhood acute lymphoblastic leukaemia.
  • [MeSH-major] Abortion, Habitual / epidemiology. Birth Weight. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology

  • MedlinePlus Health Information. consumer health - Birth Weight.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Cancer Causes Control. 2007 Mar;18(2):219-28 [17206531.001]
  • (PMID = 17828442.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] Netherlands
  •  go-up   go-down


51. Thachil J: Reduced elimination of Methotrexate in an adult with trisomy 21 and acute lymphoblastic leukaemia. Leuk Res; 2007 Oct;31(10):1452-3
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced elimination of Methotrexate in an adult with trisomy 21 and acute lymphoblastic leukaemia.
  • [MeSH-major] Antimetabolites, Antineoplastic / blood. Down Syndrome / metabolism. Methotrexate / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17178159.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


52. Aydogdu I, Erkurt AM, Kaya E, Kuku I: Bone relapse in a patient with acute lymphoblastic leukaemia. Br J Haematol; 2005 Apr;129(2):163
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone relapse in a patient with acute lymphoblastic leukaemia.
  • [MeSH-major] Bone and Bones / pathology. Magnetic Resonance Imaging. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15813842.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


53. Maillard N, Buzyn A: [Acute lymphoblastic leukaemia. Acute myeloblastic leukaemia]. Rev Prat; 2006 Feb 15;56(3):303-8
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute lymphoblastic leukaemia. Acute myeloblastic leukaemia].
  • [MeSH-major] Leukemia, Myeloid, Acute

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16583957.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


54. Fielding AK, Goldstone AH: Allogeneic haematopoietic stem cell transplant in Philadelphia-positive acute lymphoblastic leukaemia. Bone Marrow Transplant; 2008 Mar;41(5):447-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic haematopoietic stem cell transplant in Philadelphia-positive acute lymphoblastic leukaemia.
  • ALL in which the Philadelphia (Ph) chromosome is detected is one of the few diseases in which there is almost unequivocal agreement that a matched sibling allogeneic haematopoietic stem cell transplant in first CR is the most appropriate therapy for patients within certain age limits.
  • Extension of allogeneic stem cell transplant to patients without matched sibling donors or to older individuals is increasingly possible due to unrelated donors, umbilical cord blood and reduced-intensity conditioning regimens.
  • We explore the burgeoning literature on the role of tyrosine kinase inhibitors in this disease and summarize their impact on the transplant practice.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Philadelphia Chromosome. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Disease-Free Survival. Graft vs Leukemia Effect. Humans. Myeloablative Agonists / therapeutic use. Protein Kinase Inhibitors / therapeutic use. Transplantation, Homologous / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17968326.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Myeloablative Agonists; 0 / Protein Kinase Inhibitors
  • [Number-of-references] 46
  •  go-up   go-down


55. Lau KK, Weiss AR, Jones DP: Polyuria associated with high-dose methotrexate in two patients with acute lymphoblastic leukaemia. J Oncol Pharm Pract; 2005 Mar;11(1):31-3
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polyuria associated with high-dose methotrexate in two patients with acute lymphoblastic leukaemia.
  • We report two patients with leukemia treated with high dose methotrexate.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Methotrexate / adverse effects. Polyuria / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • Hazardous Substances Data Bank. Adenosine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16460601.001).
  • [ISSN] 1078-1552
  • [Journal-full-title] Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  • [ISO-abbreviation] J Oncol Pharm Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; K72T3FS567 / Adenosine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


56. Taub JW: Early T-cell precursor acute lymphoblastic leukaemia. Lancet Oncol; 2009 Feb;10(2):105-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early T-cell precursor acute lymphoblastic leukaemia.
  • [MeSH-major] Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Lancet Oncol. 2009 Feb;10(2):147-56 [19147408.001]
  • (PMID = 19185830.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] England
  •  go-up   go-down


57. Sevilla J, Díaz MA, Madero L: Extramedullary acute lymphoblastic leukaemia in childhood. Eur J Haematol; 2007 Aug;79(2):182

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extramedullary acute lymphoblastic leukaemia in childhood.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17635243.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


58. Disperati P, Ichim CV, Tkachuk D, Chun K, Schuh AC, Wells RA: Progression of myelodysplasia to acute lymphoblastic leukaemia: implications for disease biology. Leuk Res; 2006 Feb;30(2):233-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progression of myelodysplasia to acute lymphoblastic leukaemia: implications for disease biology.
  • Myelodysplastic syndrome (MDS) comprises a group of clonal haematopoietic disorders characterized by peripheral blood cytopenias, bone marrow hypercellularity, and abnormal blood cell differentiation.
  • Approximately 30% of cases of MDS eventually progress to acute myelogenous leukemia (AML), while progression of MDS into acute lymphoblastic leukemia (ALL) is rare.
  • We review the cancer stem cell model and its application to these disorders, and discuss the implications of the rarity of transformation of MDS to ALL for the biology of MDS and the pathogenesis of ALL.
  • [MeSH-major] Myelodysplastic Syndromes / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology

  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16046234.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 60
  •  go-up   go-down


59. Have a look at the other side of the work/life balance. Nurs Stand; 2007 Aug 01;21(47):32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Have a look at the other side of the work/life balance.
  • : Has nursing become the most selfish profession of all?
  • We constantly moan about night shifts, how staff shortages and deficits are detrimental to quality patient care and nursing intervention, and how this limits our ability to provide the highest standards of nursing.
  • On the other hand, I cannot help but notice how we seem to forget to look after each other when it comes to shift allocation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28001636.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


60. Jurkowska M, Malinowska I, Bal J: [Genetic polymorphism and outcome in acute lymphoblastic leukaemia of childhood]. Przegl Lek; 2005;62(12):1412-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Genetic polymorphism and outcome in acute lymphoblastic leukaemia of childhood].
  • Current treatment strategies of leukaemia use risk factors existing at the time of diagnosis to establish risk-adapted therapy.
  • This approach currently results in overall 95% rate of complete remission in paediatric acute lymphoblastic leukemia (ALL).
  • This suggests the existence of factors independent from leukaemia genetic background, which influences the outcome of patients with ALL.
  • [MeSH-major] Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Cytochrome P-450 Enzyme System / metabolism. European Continental Ancestry Group / genetics. Genetic Predisposition to Disease. Glutathione Transferase / metabolism. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16786762.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 9035-51-2 / Cytochrome P-450 Enzyme System; EC 2.5.1.18 / Glutathione Transferase
  • [Number-of-references] 33
  •  go-up   go-down


61. Sørensen GV, Helgestad J, Rosthøj S: [Herpes zoster-associated morbidity in children undergoing chemotherapy for acute lymphoblastic leukaemia]. Ugeskr Laeger; 2009 Nov 9;171(46):3350-4
Hazardous Substances Data Bank. ACYCLOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Herpes zoster-associated morbidity in children undergoing chemotherapy for acute lymphoblastic leukaemia].
  • [Transliterated title] Herpes zoster-associeret morbiditet hos børn i kemoterapi for akut lymfoblastaer leukaemi.
  • We aimed to assess morbidity from herpes zoster in children with acute lymphoblastic leukemia (ALL).
  • Of these, 45 had had varicella at the time of diagnosis and 15 contracted varicella or were vaccinated during the course of therapy.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Herpes Zoster / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • MedlinePlus Health Information. consumer health - Shingles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19925740.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antiviral Agents; X4HES1O11F / Acyclovir
  •  go-up   go-down


62. Marks DI: Conditioning regimens for acute lymphoblastic leukaemia allografts. Bone Marrow Transplant; 2007 Mar;39(6):377; author reply 378
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conditioning regimens for acute lymphoblastic leukaemia allografts.
  • [MeSH-minor] Adolescent. Child. Cyclophosphamide / administration & dosage. Etoposide / administration & dosage. Humans. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Survival Analysis. Transplantation, Homologous

  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Bone Marrow Transplant. 2006 Dec;38(11):739-43 [17013424.001]
  • (PMID = 17277787.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


63. Gupta A, Al Alenezi H, Ibrahim JM, Marouf R: Acute lymphoblastic leukaemia presenting as vasculitis. Br J Haematol; 2006 Feb;132(4):384
MedlinePlus Health Information. consumer health - Vasculitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukaemia presenting as vasculitis.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Vasculitis / etiology

  • Genetic Alliance. consumer health - Vasculitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16412013.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


64. Moghadam A, Talebi-Taher M, Dehghan A: Sacroiliitis as an initial presentation of acute lymphoblastic leukaemia. Acta Clin Belg; 2010 May-Jun;65(3):197-9
MedlinePlus Health Information. consumer health - Arthritis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sacroiliitis as an initial presentation of acute lymphoblastic leukaemia.
  • The pathologist reported Acute Lymphoblastic Leukaemia.
  • The reported patient is the first case of acute lymphoblastic leukaemia, accompanied by sacroiliitis.
  • [MeSH-major] Arthritis / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Sacroiliac Joint

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20669789.001).
  • [ISSN] 1784-3286
  • [Journal-full-title] Acta clinica Belgica
  • [ISO-abbreviation] Acta Clin Belg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


65. Idris M, Farid J, Sarwar J, Ahmed S, Wiqar MA, Badsha S: Response rate of Pakistani children with acute lymphoblastic leukaemia to Medical Research Council acute lymphoblastic leukaemia 97 chemotherapy protocol. J Ayub Med Coll Abbottabad; 2010 Jul-Sep;22(3):8-11
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response rate of Pakistani children with acute lymphoblastic leukaemia to Medical Research Council acute lymphoblastic leukaemia 97 chemotherapy protocol.
  • BACKGROUND: Acute lymphoblastic leukaemia (ALL), a malignancy of lymphoid lineage cells, has excellent prognosis in children.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Protocols. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22338406.001).
  • [ISSN] 1025-9589
  • [Journal-full-title] Journal of Ayub Medical College, Abbottabad : JAMC
  • [ISO-abbreviation] J Ayub Med Coll Abbottabad
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


66. Balduzzi A, Valsecchi MG, Uderzo C, De Lorenzo P, Klingebiel T, Peters C, Stary J, Felice MS, Magyarosy E, Conter V, Reiter A, Messina C, Gadner H, Schrappe M: Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study. Lancet; 2005 Aug 20-26;366(9486):635-42
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study.
  • BACKGROUND: The dismal prognosis of very-high-risk childhood acute lymphoblastic leukaemia could be improved by allogeneic haemopoietic cell transplantation.
  • We compared this strategy with intensified chemotherapy protocols, with the aim to improve the outcome of children with very-high-risk acute lymphoblastic leukaemia in first complete remission.
  • Very-high-risk acute lymphoblastic leukaemia in first complete remission was defined by the presence of at least one of the following criteria:.
  • (2) t(9;22) or t(4;11) clonal abnormalities; and (3) poor response to prednisone associated with T immunophenotype, white-blood-cell count of 100x10(9)/L or greater, or both.
  • Children were allocated treatment by genetic chance, according to the availability of a compatible related donor, and assigned chemotherapy or haemopoietic-cell transplantation.
  • The primary outcome was disease-free survival and analysis was by intention to treat.
  • FINDINGS: Between April, 1995, and December, 2000, 357 children entered the study, of whom 280 were assigned chemotherapy and 77 related-donor haemopoietic-cell transplantation.
  • 5-year disease-free survival was 40.6% (SE 3.1) in children allocated chemotherapy and 56.7% (5.7) in those assigned transplantation (hazard ratio 0.67 [95% CI 0.46-0.99]; p=0.02); 5-year survival was 50.1% (3.1) and 56.4% (5.9), respectively (0.73 [0.49-1.09]; p=0.12).
  • INTERPRETATION: Children with very-high-risk acute lymphoblastic leukaemia benefit from related-donor haemopoietic-cell transplantation compared with chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Male. Recurrence. Remission Induction. Risk Factors. Survival Rate. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16112299.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


67. What price this pay rise? Nurs Stand; 2007 Mar 07;21(26):1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] What price this pay rise?
  • : There was outrage when a trust suggested that staff should work a day for free to help its finances.
  • And rightly so.
  • But now it seems the same principle is being applied nationally.
  • That really is the only conclusion to be drawn from the decision to stage your 2007 pay award.
  • After all, an independent review body looked at all the evidence, including ministers' arguments about affordability, and decided that a fair award this year would be 2.5 per cent.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27967387.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


68. Dhingra B, Bhargava R, Mishra P: Acute lymphoblastic leukaemia with unusual chromosomal abnormality: t(3;9) (p21;p13), del(10p12) [13]. Leuk Res; 2009 Dec;33(12):e221-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukaemia with unusual chromosomal abnormality: t(3;9) (p21;p13), del(10p12) [13].
  • We report a case of pre-B acute lymphoblastic leukaemia with an unusual translocation between chromosome 3 and 9, with del(10p12) [13].
  • The diagnosis at presentation was made by the morphology, cytochemistry and immunophenotyping.
  • To the best of our knowledge and after literature search this appears to be a rare cytogenetic abnormality in ALL.
  • [MeSH-major] Chromosome Deletion. Chromosomes, Human, Pair 10. Chromosomes, Human, Pair 3. Chromosomes, Human, Pair 9. Leukemia, B-Cell / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19476998.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


69. McGough G: Gardening initiative is a positive example for us all. Nurs Stand; 2009 Oct 07;24(5):32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gardening initiative is a positive example for us all.
  • : I enjoyed Carol Davis's depiction of the therapeutic benefits of gardening (features September 16).
  • Research has shown that gardening - or even minimal involvement in a green space - can help with patients' recovery, and this needs to be encouraged.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28026490.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


70. Carbone K: School nurse father is a shining example to us all. Nurs Stand; 2010 Oct 20;25(7):33

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] School nurse father is a shining example to us all.
  • : What a wonderful letter from 12-year-old Elizabeth Watson (October 13) describing her school nurse father as a hero.
  • It made my day.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28019635.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


71. Smith MA, Morton CL, Carol H, Gorlick RG, Kang MH, Keir ST, Kolb EA, Lock RB, Maris JM, Houghton PJ: Pediatric Preclinical Testing Program (PPTP) testing of the CENP-E inhibitor GSK923295A. J Clin Oncol; 2009 May 20;27(15_suppl):10015

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The PPTP includes a molecularly characterized in vitro panel of cell lines (n = 27) and in vivo panel of xenografts (n = 60) representing most of the common types of childhood solid tumors and childhood acute lymphoblastic leukemia (ALL).
  • RESULTS: GSK923295A demonstrated potent in vitro activity against the PPTP cell line panel with a median IC50 of 27 nM (range 12 nM to > 10 μM).
  • For the neuroblastoma panel, the best response was progressive disease (PD) with growth delay compared to controls (PD2 response), which was observed in 5 of 6 xenografts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962529.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Cooke NS, Feighery C, Armstrong DK, Walsh M, Dempsey S: Cutaneous Fusarium solani infection in childhood acute lymphoblastic leukaemia. Clin Exp Dermatol; 2009 Jul;34(5):e117-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous Fusarium solani infection in childhood acute lymphoblastic leukaemia.
  • We describe a case of widespread cutaneous involvement after infection with Fusarium solani in childhood acute lymphoblastic leukaemia that responded successfully to treatment with prolonged liposomal amphotericin B.
  • [MeSH-major] Dermatomycoses / complications. Fusarium / isolation & purification. Opportunistic Infections / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19438533.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


73. Fløisand Y, Brinch L, Dybedal I, Gedde-Dahl T, Heldal D, Holme PA, Egeland T, Tjønnfjord GE: [Allogeneic stem cell transplantation in adults with acute lymphoblastic leukaemia]. Tidsskr Nor Laegeforen; 2008 Nov 20;128(22):2563-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Allogeneic stem cell transplantation in adults with acute lymphoblastic leukaemia].
  • [Transliterated title] Allogen stamcelletransplantasjon hos voksne med akutt lymfoblastisk leukemi.
  • BACKGROUND: The success rate for chemotherapy of adults with acute lymphoblastic leukaemia in Norway compares favourably with that in international reports, but improvements are still needed.
  • Allogeneic stem cell transplantation is an option for patients up to 60 years and may contribute to improving the outcome for these patients.
  • MATERIAL AND METHODS: Allogen stem cell transplantation was performed in 61 high-risk patients (38 men and 23 women) with acute lymphoblastic leukaemia at Rikshospitalet between 1985 and 2005.
  • 19 patients were transplanted in first remission and 42 at a later stage of the disease.
  • Estimated 5-year actuarial leukemia-free survival was 35 %.
  • INTERPRETATION: Our results are in line with international reports on the results of allogen stem cell transplantation in high-risk acute lymphoblastic leukaemia.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Disease-Free Survival. Female. Graft vs Host Disease / diagnosis. Graft vs Host Disease / prevention & control. Humans. Male. Middle Aged. Remission Induction. Risk Factors. Survival Analysis. Transplantation Conditioning. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19023351.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


74. Styczynski J, Wysocki M: Ex vivo modulation of response to prednisolone in childhood acute lymphoblastic leukaemia. Br J Haematol; 2006 May;133(4):397-9
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ex vivo modulation of response to prednisolone in childhood acute lymphoblastic leukaemia.
  • We hypothesised that the intensity of mechanisms of glucocorticoid resistance in childhood acute lymphoblastic leukaemia might be decreased by concurrent ex vivo use of compounds with specific blocking or activating properties at different steps of the glucocorticoid intracellular pathway.
  • [MeSH-major] Antineoplastic Agents, Hormonal / pharmacology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Prednisolone / pharmacology
  • [MeSH-minor] Cell Death / drug effects. Child. Drug Resistance, Neoplasm / drug effects. Drug Screening Assays, Antitumor / methods. Drug Synergism. Humans. Recurrence. Signal Transduction / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16643446.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


75. Sengul E, Dervisoglu E, Kus E, Ciftci E, Ercin C, Yilmaz A: Acute lymphoblastic leukaemia presenting with acute renal failure: report of two cases. J Pak Med Assoc; 2008 Sep;58(9):512-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukaemia presenting with acute renal failure: report of two cases.
  • Acute renal failure is a well-recognized complication of acute leukaemias.
  • Here we report two patients with acute lymphoblastic leukaemia presenting with acute renal failure due to leukaemic infiltration.
  • The first patient died before the administration of specific therapy for leukaemia, whereas the second case recovered after chemotherapy.
  • [MeSH-major] Acute Kidney Injury / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Pak Med Assoc. 2008 Dec;58(12):719
  • (PMID = 18846803.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


76. Hitoglou-Hatzi S, Hatzistilianou M, Gougoustamou D, Rekliti A, Agguridaki Ch, Athanassiadou F, Frydas S, Kotsis A, Catriu D: Serum adenosine deaminase and procalcitonin concentrations in neutropenic febrile children with acute lymphoblastic leukaemia. Clin Exp Med; 2005 Jul;5(2):60-5
Hazardous Substances Data Bank. Calcitonin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum adenosine deaminase and procalcitonin concentrations in neutropenic febrile children with acute lymphoblastic leukaemia.
  • Neutropenia as a state of immunosuppression is probably the major problem in patients suffering from acute lymphoblastic leukaemia undergoing intensive chemotherapy.
  • The aim of this work was to study sensitive markers for early diagnosis of microbial infection in neutropenic children undergoing intensive chemotherapy as a treatment for acute lymphoblastic leukaemia.
  • The study included three groups (A, B and C) of children with acute lymphoblastic leukaemia and neutropenia.
  • In conclusion, this study suggests procalcitonin and total ADA activity as two easily measurable and cost effective markers for the assessment of immune response in febrile neutropenic patients with acute lymphoblastic leukaemia.
  • [MeSH-major] Adenosine Deaminase / blood. Calcitonin / blood. Fever / blood. Neutropenia / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Protein Precursors / blood

  • MedlinePlus Health Information. consumer health - Fever.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16096855.001).
  • [ISSN] 1591-8890
  • [Journal-full-title] Clinical and experimental medicine
  • [ISO-abbreviation] Clin. Exp. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Protein Precursors; 56645-65-9 / procalcitonin; 9007-12-9 / Calcitonin; EC 3.5.4.4 / Adenosine Deaminase
  •  go-up   go-down


77. Le QH, Thomas X, Ecochard R, Iwaz J, Lhéritier V, Michallet M, Fiere D: Initial and late prognostic factors to predict survival in adult acute lymphoblastic leukaemia. Eur J Haematol; 2006 Dec;77(6):471-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial and late prognostic factors to predict survival in adult acute lymphoblastic leukaemia.
  • Factors able to predict overall survival in adult patients with acute lymphoblastic leukaemia were assessed according to the period since initiation of the treatment using a Cox proportional hazards model.
  • From 1994 to 2002, 922 patients with acute lymphoblastic leukaemia (excluding French-American-British L3 subtype) were enrolled in a multicentre protocol and followed, with a mean follow up of 58 months.
  • Determination of such factors is crucial to adapt postremission therapeutic strategies in acute lymphoblastic leukaemia.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16978239.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Denmark
  •  go-up   go-down


78. Couto E, Chen B, Hemminki K: Association of childhood acute lymphoblastic leukaemia with cancers in family members. Br J Cancer; 2005 Nov 28;93(11):1307-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of childhood acute lymphoblastic leukaemia with cancers in family members.
  • Children whose twins have had leukaemia have a higher risk of contracting acute lymphoblastic leukaemia (ALL), confirming a prenatal origin of the disease.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1999 Oct 30;354(9189):1499-503 [10551495.001]
  • [Cites] BMJ. 2005 Jun 4;330(7503):1294 [15849205.001]
  • [Cites] Br J Cancer. 2001 Feb 2;84(3):388-91 [11161404.001]
  • [Cites] Br J Cancer. 2001 Apr 6;84(7):990-3 [11286482.001]
  • [Cites] Lancet. 2001 Sep 1;358(9283):711-7 [11551577.001]
  • [Cites] Acta Oncol. 2001;40(6):772-7 [11765074.001]
  • [Cites] Cancer Causes Control. 2001 Dec;12(10):935-41 [11808713.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2321-33 [12791663.001]
  • [Cites] Cancer Detect Prev. 2004;28(2):83-7 [15068830.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6429-44 [15322515.001]
  • [Cites] Lancet. 1990 Sep 8;336(8715):577-82 [1975376.001]
  • [Cites] J Natl Cancer Inst. 1992 Mar 4;84(5):306-12 [1738180.001]
  • [Cites] Am J Epidemiol. 1992 Oct 15;136(8):916-24 [1456268.001]
  • [Cites] Br J Cancer. 1995 Jan;71(1):1-5 [7819022.001]
  • [Cites] Med Pediatr Oncol. 1996 Apr;26(4):223-9 [8600332.001]
  • [Cites] Lancet. 1997 Feb 1;349(9048):344-9 [9024390.001]
  • [Cites] Eur J Cancer. 1999 Dec;35(14):1941-53 [10711237.001]
  • (PMID = 16288301.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Twin Study
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2361521
  •  go-up   go-down


79. Protas PT, Muszynska-Roslan K, Holownia A, Grabowska A, Krawczuk-Rybak M, Braszko JJ: Cerebrospinal fluid changes in the excitatory amino acids concentration caused by the standard treatment of acute lymphoblastic leukaemia in children do not correlate with their later cognitive functioning. Neuropediatrics; 2009 Dec;40(6):295-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebrospinal fluid changes in the excitatory amino acids concentration caused by the standard treatment of acute lymphoblastic leukaemia in children do not correlate with their later cognitive functioning.
  • The aim of this study was to ascertain whether changes in the concentrations of cerebrospinal fluid excitatory amino acids (EAAs) contribute to neurotoxicity of the standard acute lymphoblastic leukaemia (ALL) treatment protocols.
  • Cognitive functioning was examined in all patients at an average of 3.7 years after the disease diagnosis.
  • [MeSH-major] Cognition / physiology. Excitatory Amino Acids / cerebrospinal fluid. Precursor Cell Lymphoblastic Leukemia-Lymphoma / cerebrospinal fluid. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Georg Thieme Verlag KG Stuttgart New York.
  • (PMID = 20446226.001).
  • [ISSN] 1439-1899
  • [Journal-full-title] Neuropediatrics
  • [ISO-abbreviation] Neuropediatrics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Excitatory Amino Acids
  •  go-up   go-down


80. Selwood K, Pizer B, Gibson B, Skinner R, United Kingdom Children's Cancer Study Group (UKCCSG)/Paediatric Oncology Nursing Forum (PONF) Supportive Care Group, and the Medical Research Council (MRC) Childhood Leukaemia Working Party (CLWP): Vascular access for daunorubicin during childhood acute lymphoblastic leukaemia induction treatment: a UKCCSG supportive care group and MRC childhood leukaemia working party survey. Eur J Oncol Nurs; 2008 Dec;12(5):476-8
Hazardous Substances Data Bank. DAUNORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular access for daunorubicin during childhood acute lymphoblastic leukaemia induction treatment: a UKCCSG supportive care group and MRC childhood leukaemia working party survey.
  • Daunorubicin was reintroduced into induction chemotherapy in UK protocols for intermediate- and high-risk childhood acute lymphoblastic leukaemia in 1999.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Catheterization, Central Venous / statistics & numerical data. Catheterization, Peripheral / statistics & numerical data. Daunorubicin / administration & dosage. Practice Patterns, Physicians' / statistics & numerical data. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18926774.001).
  • [ISSN] 1462-3889
  • [Journal-full-title] European journal of oncology nursing : the official journal of European Oncology Nursing Society
  • [ISO-abbreviation] Eur J Oncol Nurs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


81. Akyol Erikci A, Ozyurt M, Terekeci H, Ozturk A, Karabudak O, Oncu K: Oesophageal aspergillosis in a case of acute lymphoblastic leukaemia successfully treated with caspofungin alone due to liposomal amphotericin B induced severe hepatotoxicity. Mycoses; 2009 Jan;52(1):84-6
Hazardous Substances Data Bank. CASPOFUNGIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oesophageal aspergillosis in a case of acute lymphoblastic leukaemia successfully treated with caspofungin alone due to liposomal amphotericin B induced severe hepatotoxicity.
  • We present an 18-year-old male with acute lymphoblastic leukaemia with aspergillosis of oesophagus which is a rare region of involvement.
  • The diagnosis was confirmed by the examination of the cultures of endoscopic biopsy material.
  • [MeSH-major] Amphotericin B / toxicity. Antifungal Agents / therapeutic use. Antifungal Agents / toxicity. Aspergillosis / diagnosis. Aspergillosis / drug therapy. Echinocandins / therapeutic use. Esophageal Diseases / drug therapy. Esophageal Diseases / microbiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • Genetic Alliance. consumer health - Aspergillosis.
  • MedlinePlus Health Information. consumer health - Aspergillosis.
  • MedlinePlus Health Information. consumer health - Esophagus Disorders.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18498301.001).
  • [ISSN] 1439-0507
  • [Journal-full-title] Mycoses
  • [ISO-abbreviation] Mycoses
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Echinocandins; 0 / liposomal amphotericin B; 7XU7A7DROE / Amphotericin B; F0XDI6ZL63 / caspofungin
  •  go-up   go-down


82. Kuchinskaya E, Heyman M, Nordgren A, Schoumans J, Staaf J, Borg A, Söderhäll S, Grandér D, Nordenskjöld M, Blennow E: Array-CGH reveals hidden gene dose changes in children with acute lymphoblastic leukaemia and a normal or failed karyotype by G-banding. Br J Haematol; 2008 Mar;140(5):572-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Array-CGH reveals hidden gene dose changes in children with acute lymphoblastic leukaemia and a normal or failed karyotype by G-banding.
  • A tiling path 33K BAC array was used to study 28 children with acute lymphoblastic leukaemia (ALL) who had normal or failed G-banded karyotypes.
  • Molecular cytogenetic and array comparative genomic hybridization results enabled the division of B-precursor ALL patients into five groups: high hyperdiploidy, intrachromosomal amplification of 21q, ETV6/RUNX1 rearrangement, others and no CNA.
  • [MeSH-major] Chromosome Aberrations. Gene Dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18275435.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


83. Catchpoole D, Lail A, Guo D, Chen QR, Khan J: Gene expression profiles that segregate patients with childhood acute lymphoblastic leukaemia: an independent validation study identifies that endoglin associates with patient outcome. Leuk Res; 2007 Dec;31(12):1741-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiles that segregate patients with childhood acute lymphoblastic leukaemia: an independent validation study identifies that endoglin associates with patient outcome.
  • In this report, we determine whether genes identified in a previously reported cDNA microarray investigation of childhood acute lymphoblastic leukaemia (ALL) diagnostic bone marrow have the same distinguishing power in an independently derived cDNA microarray dataset from an equivalent but distinct patient cohort.
  • [MeSH-major] Antigens, CD / analysis. Gene Expression Profiling. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Receptors, Cell Surface / analysis
  • [MeSH-minor] Cell Lineage. Humans. Lymphocytes / pathology. Neural Networks (Computer). Oligonucleotide Array Sequence Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17572488.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / ENG protein, human; 0 / Receptors, Cell Surface
  •  go-up   go-down


84. Gassas A, Ishaqi MK, Afzal S, Dupuis A, Doyle J: Outcome of haematopoietic stem cell transplantation for paediatric acute lymphoblastic leukaemia in third complete remission: a vital role for graft-versus-host-disease/ graft-versus-leukaemia effect in survival. Br J Haematol; 2008 Jan;140(1):86-9
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of haematopoietic stem cell transplantation for paediatric acute lymphoblastic leukaemia in third complete remission: a vital role for graft-versus-host-disease/ graft-versus-leukaemia effect in survival.
  • Children with acute lymphoblastic leukaemia (ALL) receiving haematopoietic stem cell transplantation (HSCT) in third complete remission (CR3) are at high risk for transplant-related mortality (TRM) and relapse.
  • Ten patients died of TRM, seven patients relapsed, six did not have graft-versus-host disease (GVHD).
  • [MeSH-major] Graft vs Host Disease / mortality. Graft vs Leukemia Effect. Hematopoietic Stem Cell Transplantation / methods. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Male. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17894841.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


85. Nowicki M, Ostalska-Nowicka D, Miskowiak B: In vitro substance P-dependent induction of bone marrow cells in common (CD10) acute lymphoblastic leukaemia. Leuk Res; 2008 Jan;32(1):97-102
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro substance P-dependent induction of bone marrow cells in common (CD10) acute lymphoblastic leukaemia.
  • The aim of the present research was to investigate the possible in vitro stimulatory effect of substance P (SP) on blasts induction in childhood common acute lymphoblastic leukaemia (ALL).
  • [MeSH-minor] Adolescent. Bone Marrow Cells. Cell Proliferation. Child. Child, Preschool. Female. Humans. Interleukin-1beta / metabolism. Male. Neurokinin-1 Receptor Antagonists. Precursor Cell Lymphoblastic Leukemia-Lymphoma

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Res. 2008 Jan;32(1):3-4 [17618685.001]
  • (PMID = 17588657.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interleukin-1beta; 0 / Neurokinin-1 Receptor Antagonists; 33507-63-0 / Substance P; 91224-37-2 / spantide
  •  go-up   go-down


86. Semsei AF, Erdélyi DJ, Ungvári I, Kámory E, Csókay B, Andrikovics H, Tordai A, Cságoly E, Falus A, Kovács GT, Szalai C: Association of some rare haplotypes and genotype combinations in the MDR1 gene with childhood acute lymphoblastic leukaemia. Leuk Res; 2008 Aug;32(8):1214-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of some rare haplotypes and genotype combinations in the MDR1 gene with childhood acute lymphoblastic leukaemia.
  • To investigate their possible roles in disease susceptibility and some disease characteristics we genotyped C3435T and G2677T/A polymorphisms in multidrug resistance-1 (MDR1) gene with a single base extension method and the G34A and C421A polymorphisms of the breast cancer resistance protein gene with an allelic discrimination system in 396 children with acute lymphoblastic leukaemia (ALL) and 192 control patients.
  • [MeSH-major] P-Glycoprotein / genetics. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Res. 2008 Aug;32(8):1173-5 [18294687.001]
  • (PMID = 18243305.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / P-Glycoprotein
  •  go-up   go-down


87. Oram SH, Thoms JA, Pridans C, Janes ME, Kinston SJ, Anand S, Landry JR, Lock RB, Jayaraman PS, Huntly BJ, Pimanda JE, Göttgens B: A previously unrecognized promoter of LMO2 forms part of a transcriptional regulatory circuit mediating LMO2 expression in a subset of T-acute lymphoblastic leukaemia patients. Oncogene; 2010 Oct 28;29(43):5796-808

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A previously unrecognized promoter of LMO2 forms part of a transcriptional regulatory circuit mediating LMO2 expression in a subset of T-acute lymphoblastic leukaemia patients.
  • The T-cell oncogene Lim-only 2 (LMO2) critically influences both normal and malignant haematopoiesis.
  • LMO2 is not normally expressed in T cells, yet ectopic expression is seen in the majority of T-acute lymphoblastic leukaemia (T-ALL) patients with specific translocations involving LMO2 in only a subset of these patients.
  • Ectopic lmo2 expression in thymocytes of transgenic mice causes T-ALL, and retroviral vector integration into the LMO2 locus was implicated in the development of clonal T-cell disease in patients undergoing gene therapy.
  • Using array-based chromatin immunoprecipitation, we now demonstrate that in contrast to B-acute lymphoblastic leukaemia, human T-ALL samples largely use promoter elements with little influence from distal enhancers.
  • Active LMO2 promoter elements in T-ALL included a previously unrecognized third promoter, which we demonstrate to be active in cell lines, primary T-ALL patients and transgenic mice.
  • [MeSH-major] DNA-Binding Proteins / genetics. Gene Expression Regulation, Neoplastic / genetics. Metalloproteins / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Promoter Regions, Genetic / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20676125.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] United Kingdom / National Centre for the Replacement, Refinement and Reduction of Animals in Research / / G0900729/1; United Kingdom / Medical Research Council / / G0800784; United Kingdom / Medical Research Council / / ; United Kingdom / Cancer Research UK / / ; United Kingdom / Medical Research Council / / G116/187
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / DNA-Binding Proteins; 0 / ERG protein, human; 0 / FLI1 protein, human; 0 / HHEX protein, human; 0 / Homeodomain Proteins; 0 / LIM Domain Proteins; 0 / LMO2 protein, human; 0 / Metalloproteins; 0 / Proto-Oncogene Protein c-fli-1; 0 / Proto-Oncogene Proteins; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Transcriptional Regulator ERG
  •  go-up   go-down


88. McNeer JL, Nachman JB: The optimal use of steroids in paediatric acute lymphoblastic leukaemia: no easy answers. Br J Haematol; 2010 Jun;149(5):638-52
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The optimal use of steroids in paediatric acute lymphoblastic leukaemia: no easy answers.
  • Glucocorticoids are an integral component of therapy for acute lymphoblastic leukaemia (ALL), but usage differs between cooperative group protocols.
  • Issues to consider in the choice of induction steroid include impact on event-free and overall survival, acute morbidity such as infection risk, diabetes, and behavioural disturbances and long-term complications such as avascular necrosis.
  • [MeSH-major] Glucocorticoids / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20408842.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glucocorticoids; 7S5I7G3JQL / Dexamethasone; VB0R961HZT / Prednisone
  • [Number-of-references] 56
  •  go-up   go-down


89. Pui CH, Jeha S: New therapeutic strategies for the treatment of acute lymphoblastic leukaemia. Nat Rev Drug Discov; 2007 Feb;6(2):149-65
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New therapeutic strategies for the treatment of acute lymphoblastic leukaemia.
  • Although contemporary treatments cure more than 80% of children with acute lymphoblastic leukaemia (ALL), some patients require intensive treatment and many patients still develop serious acute and late complications owing to the side effects of the treatments.
  • These include new formulations of existing chemotherapeutic agents, new antimetabolites and nucleoside analogues, monoclonal antibodies against leukaemia-associated antigens, and molecular therapies that target genetic abnormalities of the leukaemic cells and their affected signalling pathways.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17268486.001).
  • [ISSN] 1474-1776
  • [Journal-full-title] Nature reviews. Drug discovery
  • [ISO-abbreviation] Nat Rev Drug Discov
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Nucleosides
  • [Number-of-references] 166
  •  go-up   go-down


90. Meijerink JP: Genetic rearrangements in relation to immunophenotype and outcome in T-cell acute lymphoblastic leukaemia. Best Pract Res Clin Haematol; 2010 Sep;23(3):307-18

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic rearrangements in relation to immunophenotype and outcome in T-cell acute lymphoblastic leukaemia.
  • Mutually exclusive oncogenic rearrangements may delineate specific T-cell acute lymphoblastic leukaemia (T-ALL) subgroups, and so far at least 4 molecular-cytogenetic subgroups have been identified, i.e. the TAL/LMO, the TLX1/HOX11, the TLX3/HOX11L2 and the HOXA subgroups.
  • A fifth group with an immature immunophenotype that can be predicted by an early T-cell precursor signature has also been identified, and has been associated with poor outcome.
  • The association of these subgroups with the expression of specific immunophenotypic markers reflecting arrest at specific T-cell developmental stages will be reviewed.
  • [MeSH-major] Gene Rearrangement. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Signal Transduction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 21112032.001).
  • [ISSN] 1532-1924
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / NOTCH1 protein, human; 0 / Proto-Oncogene Proteins; 0 / Receptor, Notch1; 135471-20-4 / TAL1 protein, human
  •  go-up   go-down


91. Gaikwad A, Rye CL, Devidas M, Heerema NA, Carroll AJ, Izraeli S, Plon SE, Basso G, Pession A, Rabin KR: Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia. Br J Haematol; 2009 Mar;144(6):930-2
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia.
  • Recurrent, prognostically significant chromosomal abnormalities occur in approximately 75% of paediatric acute lymphoblastic leukaemia (ALL), but only infrequently in children with Down syndrome (DS) and ALL.

  • Genetic Alliance. consumer health - Down Syndrome.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2007 Mar 1;109(5):2202-4 [17068151.001]
  • [Cites] Lancet. 2008 Oct 25;372(9648):1484-92 [18805579.001]
  • [Cites] Br J Cancer. 1977 Jan;35(1):1-39 [831755.001]
  • [Cites] Lancet. 2000 Jan 15;355(9199):165-9 [10675114.001]
  • [Cites] Nat Genet. 2002 Sep;32(1):148-52 [12172547.001]
  • [Cites] Blood. 2009 Jan 15;113(3):646-8 [18927438.001]
  • (PMID = 19120350.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K12 CA090433; United States / NCI NIH HHS / CA / K12 CA090433-06; United States / NCI NIH HHS / CA / CA90433-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.2 / Janus Kinase 2
  • [Other-IDs] NLM/ NIHMS127709; NLM/ PMC2724897
  •  go-up   go-down


92. Meier M, den Boer ML, Hall AG, Irving JA, Passier M, Minto L, van Wering ER, Janka-Schaub GE, Pieters R: Relation between genetic variants of the ataxia telangiectasia-mutated (ATM) gene, drug resistance, clinical outcome and predisposition to childhood T-lineage acute lymphoblastic leukaemia. Leukemia; 2005 Nov;19(11):1887-95
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relation between genetic variants of the ataxia telangiectasia-mutated (ATM) gene, drug resistance, clinical outcome and predisposition to childhood T-lineage acute lymphoblastic leukaemia.
  • The T-lineage phenotype in children with acute lymphoblastic leukaemia (ALL) is associated with in vitro drug resistance and a higher relapse-risk compared to a precursor B phenotype.
  • Our study was aimed to investigate whether mutations in the ATM gene occur in childhood T-lineage acute lymphoblastic leukaemia (T-ALL) that are linked to drug resistance and clinical outcome.
  • However, T-ALL patients carrying these five coding alterations presented with a higher white blood cell count at diagnosis (P = 0.05) and show an increased relapse-risk (5-year probability of disease-free survival (pDFS) = 48%) compared to patients with other alterations or wild-type ATM (5-year pDFS = 76%, P = 0.05).
  • The association between five coding ATM alterations in T-ALL, their germline presence, white blood cell count and unfavourable outcome may point to a role for ATM in the development of T-ALL in these children.
  • [MeSH-major] Cell Cycle Proteins / genetics. DNA-Binding Proteins / genetics. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / genetics. Polymorphism, Single Nucleotide. Protein-Serine-Threonine Kinases / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Antibiotics, Antineoplastic / pharmacology. Ataxia Telangiectasia Mutated Proteins. Case-Control Studies. Child. Child, Preschool. Daunorubicin / pharmacology. Disease-Free Survival. Drug Resistance, Neoplasm / genetics. Female. Gene Expression Profiling. Genetic Predisposition to Disease. Humans. Infant. Leukocyte Count. Male. Middle Aged. Phenotype. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. Risk Factors

  • Genetic Alliance. consumer health - Ataxia.
  • Genetic Alliance. consumer health - Ataxia Telangiectasia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leukemia. 2006 Mar;20(3):526-7; author reply 527 [16408093.001]
  • (PMID = 16167060.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Tumor Suppressor Proteins; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


93. Krawczuk-Rybak M, Solarz E, Wojtkowska M, Wysocka J: [Gonadal function in boys prior to treatment for acute lymphoblastic leukaemia]. Med Wieku Rozwoj; 2008 Oct-Dec;12(4 Pt 2):1008-13
Hazardous Substances Data Bank. MENOTROPINS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gonadal function in boys prior to treatment for acute lymphoblastic leukaemia].
  • The aim of this study was to evaluate the gonadal function in boys with newly-diagnosed acute lymphoblastic leukaemia, prior to therapy.
  • PATIENTS AND METHODS: The analysis was evaluated in 48 boys with acute lymphoblastic leukaemia, at the time of diagnosis; 34 boys were prepubertal - Tanner stage of sexual maturation 1 (group I) and 14 - pubertal - Tanner stage 3-5 (group II).
  • CONCLUSION: In adolescent boys with newly diagnosed leukaemia, lowered inhibin B values may suggest the damage of spermatogenesis even before the start of chemo- and radiotherapy.
  • [MeSH-major] Gonadal Disorders / blood. Gonadal Disorders / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • Hazardous Substances Data Bank. TESTOSTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19531817.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / inhibin B; 3XMK78S47O / Testosterone; 57285-09-3 / Inhibins; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


94. Izraeli S: Application of genomics for risk stratification of childhood acute lymphoblastic leukaemia: from bench to bedside? Br J Haematol; 2010 Oct;151(2):119-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Application of genomics for risk stratification of childhood acute lymphoblastic leukaemia: from bench to bedside?
  • The remarkable progress in the treatment of childhood acute lymphoblastic leukaemia (ALL) has been based on the adjustment of therapy to subgroups of leukaemia stratified by their prognostic implications.
  • The application of genomics for routine diagnosis of ALL is feasible but depends on commercial development of appropriate certified platforms.
  • [MeSH-major] Genomics / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Ltd.
  • (PMID = 20678159.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  •  go-up   go-down


95. Drabko K, Bojarska-Junak A, Kowalczyk J: [Activity of superoxide dismutase and glutathione peroxidase and concentrations of malonyldialdehyde, vitamin E, total antioxidant status and extracellular cytokines concentrations in children with acute lymphoblastic leukaemia (ALL)]. Med Wieku Rozwoj; 2006 Jul-Sep;10(3 Pt 1):861-8
Hazardous Substances Data Bank. MALONALDEHYDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Activity of superoxide dismutase and glutathione peroxidase and concentrations of malonyldialdehyde, vitamin E, total antioxidant status and extracellular cytokines concentrations in children with acute lymphoblastic leukaemia (ALL)].
  • THE AIM of this study was to measure oxidative status (MDA) and antioxidant defence (Zn-Cu SOD, GPX, Vitamin E and TAS) in peripheral blood of children with acute lymphoblastic leukaemia (ALL) and assess the influence of oxidative-antioxidative balance on extra cellular IL-2, IL-4, IL-5, IL-10, TNF-alpha and INF gamma concentration.
  • MATERIAL AND METHODS: The study group consisted of 17 children, diagnosed as having acute lymphoblastic leukemia and admitted to our department between February and December 2004.
  • MDA levels were higher in leukaemia group then in controls (p<0.05).
  • CONCLUSIONS: In children with acute lymphoblastic leukaemia, abnormalities in oxidative-antioxidative balance are observed.
  • [MeSH-major] Antioxidants / metabolism. Cytokines / blood. Glutathione Peroxidase / blood. Malondialdehyde / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Superoxide Dismutase / blood. Vitamin E / blood

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Vitamin E.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317918.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Cytokines; 1406-18-4 / Vitamin E; 4Y8F71G49Q / Malondialdehyde; EC 1.11.1.9 / Glutathione Peroxidase; EC 1.15.1.1 / Superoxide Dismutase
  •  go-up   go-down


96. Dockerty JD, Herbison P, Skegg DC, Elwood M: Vitamin and mineral supplements in pregnancy and the risk of childhood acute lymphoblastic leukaemia: a case-control study. BMC Public Health; 2007;7:136
Hazardous Substances Data Bank. FOLIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vitamin and mineral supplements in pregnancy and the risk of childhood acute lymphoblastic leukaemia: a case-control study.
  • BACKGROUND: An earlier case-control study from Western Australia reported a protective effect of maternal folic acid supplementation during pregnancy on the risk of childhood acute lymphoblastic leukaemia (ALL).
  • [MeSH-major] Dietary Supplements / utilization. Folic Acid / therapeutic use. Iron, Dietary / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / prevention & control

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Dietary Supplements.
  • MedlinePlus Health Information. consumer health - Folic Acid.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Causes Control. 2004 Aug;15(6):559-70 [15280635.001]
  • [Cites] Br J Cancer. 1996 May;73(9):1141-7 [8624278.001]
  • [Cites] Br J Cancer. 1999 Jul;80(9):1483-9 [10424755.001]
  • [Cites] Birth Defects Res A Clin Mol Teratol. 2004 Nov;70(11):842-3 [15523662.001]
  • [Cites] Cancer Causes Control. 2004 Nov;15(9):931-7 [15577295.001]
  • [Cites] Haematologica. 2004 Feb;89(2):139-44 [15003888.001]
  • [Cites] Am J Epidemiol. 2007 Jan 1;165(1):27-35 [17035343.001]
  • [Cites] Lancet. 1999 Dec 4;354(9194):1967-8 [10622301.001]
  • [Cites] Lancet. 2001 Dec 8;358(9297):1935-40 [11747917.001]
  • [Cites] N Z Med J. 2003 Jan 24;116(1168):U303 [12601426.001]
  • [Cites] Am J Epidemiol. 2003 Apr 1;157(7):571-82 [12672676.001]
  • [Cites] BMC Med Genet. 2005 May 27;6:23 [15921520.001]
  • (PMID = 17605825.001).
  • [ISSN] 1471-2458
  • [Journal-full-title] BMC public health
  • [ISO-abbreviation] BMC Public Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Iron, Dietary; 0 / Minerals; 0 / Vitamins; 935E97BOY8 / Folic Acid
  • [Other-IDs] NLM/ PMC1925082
  •  go-up   go-down


97. Juarez JG, Thien M, Dela Pena A, Baraz R, Bradstock KF, Bendall LJ: CXCR4 mediates the homing of B cell progenitor acute lymphoblastic leukaemia cells to the bone marrow via activation of p38MAPK. Br J Haematol; 2009 May;145(4):491-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CXCR4 mediates the homing of B cell progenitor acute lymphoblastic leukaemia cells to the bone marrow via activation of p38MAPK.
  • The mechanisms regulating the migration of leukaemic cells between the blood and bone marrow compartments remain obscure, but are of fundamental importance for the dissemination of the disease.
  • This study investigated the in vivo homing of human B cell progenitor acute lymphoblastic leukaemia (ALL) cells to the femoral bone marrow of non-obese diabetic severe combined immunodeficient (NOD/SCID) mice.
  • In contrast, the homing of normal peripheral blood CD34(+) cells and the cytokine-dependent CD34(+) cell line Mo7e was independent of p38MAPK, consistent with the dependence of these cells, as well as normal CD34(+) CD19(+) B cell progenitors, on PI-3K/AKT signalling.
  • Altogether, our data provide clarification of the direct role of CXCL12 in the bone marrow homing of ALL cells and demonstrate unique signalling molecule usage that may have therapeutic implications for this disease.
  • [MeSH-major] B-Lymphocytes / physiology. Chemotaxis, Leukocyte / physiology. Neoplastic Stem Cells / physiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Receptors, CXCR4 / metabolism. p38 Mitogen-Activated Protein Kinases / metabolism
  • [MeSH-minor] Animals. Bone Marrow / immunology. Cell Line, Tumor. Chemokine CXCL12 / metabolism. Chromones / pharmacology. Enzyme Activation. Enzyme Inhibitors / pharmacology. Flavonoids / pharmacology. Heterocyclic Compounds / pharmacology. Humans. Imidazoles / pharmacology. Mice. Mice, Inbred NOD. Mice, SCID. Morpholines / pharmacology. Oligopeptides / pharmacology. Phosphatidylinositol 3-Kinases / antagonists & inhibitors. Protein Binding

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19344405.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; 0 / Chemokine CXCL12; 0 / Chromones; 0 / Enzyme Inhibitors; 0 / Flavonoids; 0 / Heterocyclic Compounds; 0 / Imidazoles; 0 / Morpholines; 0 / Oligopeptides; 0 / Receptors, CXCR4; 0 / SB202494; 0 / TC14012; 154447-36-6 / 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; 155148-31-5 / JM 3100; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
  •  go-up   go-down


98. Meisel R, Toschke AM, Heiligensetzer C, Dilloo D, Laws HJ, von Kries R: Increased risk for invasive pneumococcal diseases in children with acute lymphoblastic leukaemia. Br J Haematol; 2007 Jun;137(5):457-60
MedlinePlus Health Information. consumer health - Pneumococcal Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased risk for invasive pneumococcal diseases in children with acute lymphoblastic leukaemia.
  • Asplenia and other conditions of immunodeficiency are established risk factors for invasive pneumococcal disease (IPD).
  • There are no current data available on the risk of IPD in children with acute lymphoblastic leukaemia (ALL), the most common type of childhood malignancy.
  • [MeSH-major] Pneumococcal Infections / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / microbiology. Streptococcus pneumoniae

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488489.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


99. Sim JP, Kho BC, Liu HS, Yung R, Chan JC: Candida tropicalis arthritis of the knee in a patient with acute lymphoblastic leukaemia: successful treatment with caspofungin. Hong Kong Med J; 2005 Apr;11(2):120-3
Hazardous Substances Data Bank. CASPOFUNGIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Candida tropicalis arthritis of the knee in a patient with acute lymphoblastic leukaemia: successful treatment with caspofungin.
  • We report a case of Candida tropicalis arthritis of the knee that occurred in a patient with acute lymphoblastic leukaemia during the recovery phase of post-chemotherapy neutropenia.
  • The arthritis resolved after 7 weeks of combination therapy with caspofungin, a new echinocandin class of antifungal agent that acts primarily on the cell wall.

  • Genetic Alliance. consumer health - Arthritis.
  • MedlinePlus Health Information. consumer health - Infectious Arthritis.
  • MedlinePlus Health Information. consumer health - Yeast Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15815067.001).
  • [ISSN] 1024-2708
  • [Journal-full-title] Hong Kong medical journal = Xianggang yi xue za zhi
  • [ISO-abbreviation] Hong Kong Med J
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Echinocandins; 0 / Peptides, Cyclic; F0XDI6ZL63 / caspofungin
  •  go-up   go-down


100. Jansen NC, Kingma A, Schuitema A, Bouma A, Huisman J, Veerman AJ, Kamps WA: Post-treatment intellectual functioning in children treated for acute lymphoblastic leukaemia (ALL) with chemotherapy-only: a prospective, sibling-controlled study. Eur J Cancer; 2006 Nov;42(16):2765-72

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-treatment intellectual functioning in children treated for acute lymphoblastic leukaemia (ALL) with chemotherapy-only: a prospective, sibling-controlled study.
  • Intellectual functioning (verbal, performance and full-scale IQ) in 43 children treated for acute lymphoblastic leukaemia (ALL) with chemotherapy-only was evaluated in a nationwide, prospective, sibling-controlled study.
  • Intellectual assessment was performed at diagnosis and repeated shortly after cessation of 2 years treatment, including intrathecal and systemic chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Intelligence. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16935489.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down






Advertisement